ATE226087T1 - Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon - Google Patents

Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon

Info

Publication number
ATE226087T1
ATE226087T1 AT99936659T AT99936659T ATE226087T1 AT E226087 T1 ATE226087 T1 AT E226087T1 AT 99936659 T AT99936659 T AT 99936659T AT 99936659 T AT99936659 T AT 99936659T AT E226087 T1 ATE226087 T1 AT E226087T1
Authority
AT
Austria
Prior art keywords
cell death
synergism
interferon
inducing agents
novel cell
Prior art date
Application number
AT99936659T
Other languages
English (en)
Inventor
Marcel Koken
Frederique Quignon
The Hugues De
Jean-Claude Ameisen
Bels Frederic De
Original Assignee
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Centre Nat Rech Scient filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE226087T1 publication Critical patent/ATE226087T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coils Or Transformers For Communication (AREA)
  • Inorganic Fibers (AREA)
  • Filters And Equalizers (AREA)
  • Peptides Or Proteins (AREA)
AT99936659T 1998-07-31 1999-07-30 Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon ATE226087T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9809886A FR2781674B1 (fr) 1998-07-31 1998-07-31 Utilisation de nouveaux agents inducteurs de mort cellulaire en synergie avec les interferons
PCT/FR1999/001901 WO2000007616A2 (fr) 1998-07-31 1999-07-30 Utilisation de nouveaux agents inducteurs de mort cellulaire en synergie avec les interferons

Publications (1)

Publication Number Publication Date
ATE226087T1 true ATE226087T1 (de) 2002-11-15

Family

ID=9529292

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99936659T ATE226087T1 (de) 1998-07-31 1999-07-30 Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon

Country Status (11)

Country Link
US (1) US7217413B1 (de)
EP (1) EP1100528B1 (de)
JP (3) JP2002522395A (de)
AT (1) ATE226087T1 (de)
AU (1) AU5168099A (de)
DE (1) DE69903559T2 (de)
DK (1) DK1100528T3 (de)
ES (1) ES2181461T3 (de)
FR (1) FR2781674B1 (de)
PT (1) PT1100528E (de)
WO (1) WO2000007616A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ296799A0 (en) 1999-09-20 1999-10-14 Unisearch Limited A cell-membrane impermeable trivalent organoarsenical derivative and use thereof
AUPR379801A0 (en) 2001-03-19 2001-04-12 Unisearch Limited Use of a substantially cell membrane impermeable compound for treating arthritis
AUPR874601A0 (en) 2001-11-08 2001-11-29 Unisearch Limited Selective targeting of apoptotic cells
FR2838965B1 (fr) 2002-04-26 2004-06-25 Centre Nat Rech Scient Therapie par l'arsenic du syndrome autoimmunlymphoproliferatif de type apls chez la souris comme chez l'homme
US8394422B2 (en) 2002-04-26 2013-03-12 Centre National De La Recherche Scientifique (Cnrs) Arsenic therapy for autoimmune and/or inflammatory diseases in mice and humans
JP2006503852A (ja) * 2002-09-25 2006-02-02 ユニバーシティー オブ ロチェスター 抗癌薬としてのカスパーゼインヒビター
EP1563099B1 (de) 2002-11-07 2009-07-22 Newsouth Innovations Pty Limited Induktion der mitochondrialen permeabilitätstransition
JP2010222289A (ja) * 2009-03-23 2010-10-07 Tokyoto Igaku Kenkyu Kiko 細胞死を予防するための医薬剤
WO2011073739A1 (en) * 2009-12-15 2011-06-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, pharmaceutical compositions and kits for use in the treatment of adult t-cell leukemia/lymphoma
WO2018134260A1 (en) * 2017-01-18 2018-07-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
JP7336359B2 (ja) * 2019-03-13 2023-08-31 株式会社明電舎 配電系統制御装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
US20020001841A1 (en) * 1998-06-26 2002-01-03 Keld Kaltoft Continuous t-cell lines
IL154589A0 (en) * 2000-08-25 2003-09-17 Aventis Pharma Inc Membrane penetrating peptides and uses thereof

Also Published As

Publication number Publication date
PT1100528E (pt) 2002-12-31
WO2000007616A2 (fr) 2000-02-17
FR2781674B1 (fr) 2002-06-28
JP2002522395A (ja) 2002-07-23
DE69903559T2 (de) 2003-02-27
EP1100528B1 (de) 2002-10-16
EP1100528A2 (de) 2001-05-23
AU5168099A (en) 2000-02-28
WO2000007616A3 (fr) 2000-04-20
FR2781674A1 (fr) 2000-02-04
US7217413B1 (en) 2007-05-15
ES2181461T3 (es) 2003-02-16
DE69903559D1 (de) 2002-11-21
JP2014129404A (ja) 2014-07-10
DK1100528T3 (da) 2002-11-04
JP2011190280A (ja) 2011-09-29

Similar Documents

Publication Publication Date Title
ES8606289A1 (es) Un procedimiento para la preparacion de piridazinaminas.
NO960743L (no) Cellulære preparater, deres fremstilling og terapeutiske anvendelse
DE69514342D1 (de) Modifizierte polypeptide mit erhoehter biologischer aktivitaet
DE69837393D1 (de) Stimulierung von hämatopoietischen zellen im vitro
DE68912331D1 (de) Erniedrigung der zellvermehrung und steigerung der killerzellenaktivität.
DE3382390D1 (de) Zellinien und ihre verwendung in der herstellung von proteinen.
CY1108459T1 (el) Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων
ES2043607T3 (es) Agentes fibrinoliticos modificados.
ATE226087T1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
FR2662698B1 (de)
DK1032672T3 (da) DNA19355-polypeptid, en tumornekrosefaktor-homolog
TR199902730T2 (xx) Glikrizikasit ve antiviral etkinlik kazand�r�lm�� en az�ndan bir proteini i�eren farmas�tik antiviral bile�im.
ATE75778T1 (de) Immunosuppressionsfaktor.
TR199802648A2 (xx) Gen tedavisi i�in n�klein asit yap�lar�.
NO162775C (no) Isolator for anvendelse i elektrolyseceller.
NZ503401A (en) Use of interferon-beta (IFN-B) genes for the treatment of cancer
ATE71149T1 (de) Monoklonale antikoerper.
DE3682358D1 (de) Expressionsvektoren zur verwendung in e. coli.
IL108584A0 (en) Cloning of interferon - alpha beta binding protein
FI840104A7 (fi) Yhdistelmä-DNA-ekspressoimisvektoreita, jotka ovat käyttökelpoisia Bacillus- ja muissa isäntäsoluissa.
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
ATE320266T1 (de) Induktion von antigen-spezifischen t-zellen durch interferon
IT8420419V0 (it) Struttura di testa, provvista di occhi mobili, applicabili su pupazzi in genere.
ATE52031T1 (de) Plasmaproteinkonzentrate mit reduzierter thrombogenizitaet und deren verwendung in klinischer ersatztherapie.
ES285527U (es) Estante perfeccionado

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1100528

Country of ref document: EP

REN Ceased due to non-payment of the annual fee